Point State Capital LP Sage Therapeutics, Inc. Transaction History

Point State Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $1.46 Million - $2.08 Million	-36,200 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $1.99 Million - $2.87 Million	36,200 New	36,200 $2.06 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $355,640 - $1.05 Million	-13,600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $818,448 - $2.1 Million	13,600 New	13,600 $982,000

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.